Clinitek Status®+ Analyzer
The CLINITEK Status+ Urine Chemistry Analyzer is a portable, easy to use analyzer. It is designed to read only Siemens Healthcare Diagnostics Reagent Strips for Urinalysis and Clinitest®…
The CLINITEK Status+ Urine Chemistry Analyzer is a portable, easy to use analyzer. It is designed to read only Siemens Healthcare Diagnostics Reagent Strips for Urinalysis and Clinitest® hCG tests. This analyzer is intended for the measurement of the following inurine: Albumin, Bibilirubin, Blood (Occult), Creatinine, Glucose, Ketone, Leukocytes, Nitrite, pH, Protein, Protein-to-Creatinine Ratio, Albumin-to-Creatinine Ratio, Specific Gravity, Urobilinogen, and human Chorionic Gonadotropin (hCG).
Who Else Makes It
Concentrated in Zhejiang (1), Guangxi (1), Chongqing (1). 2 of them are registered as contract manufacturers, able to build to a buyer’s own specification.
| Manufacturer | City | Province | Registered as | Device types |
|---|---|---|---|---|
| Acon Biotech (Hangzhou) Co., Ltd. | Hangzhou | Zhejiang | Contract manufacturer | 29 |
| Dongguan Honfield Precision Parts Co., Ltd. | Zhangmutou, Dongguan | Guangdong | Contract manufacturer | 8 |
| Urit Medical Electronic Co., Ltd. | Guilin | Guangxi | Contract manufacturer | 28 |
| Chong Qing Teco Huayi Pharm. Co. | Shapingba Dist. | Chongqing | Contract manufacturer | 18 |
Record
| Listed by | Siemens Healthcare Diagnostics Inc, United States |
|---|---|
| FDA product code | JFY |
| Device type | Enzymatic Method, Creatinine |
| Device class | Class 2 |
| Regulation | 21 CFR 862.1225 |
| Establishment | Contract manufacturer, Specification developer, Repacker / relabeller, Complaint-file establishment, Manufacturer, Exporter |
| 510(k) | K091216 |
| Record published | 2016-09-24 |
| Record revised | 2021-11-19 (version 5) |
Specifications
| MRI safety | Labeling does not contain MRI Safety Information |
|---|---|
| Label carries | serial number |
| Storage | Special storage condition: Max 95% RH at 45’c; Handling environment temperature -20 to 60 °C; Storage environment temperature 5 to 40 °C |
Catalogue Numbers
| Catalogue number | Size | Status |
|---|---|---|
| 10379675 | In distribution |
Same Product Code
| Product | Sold by | Catalogue numbers |
|---|---|---|
| Creatinine Plus | Roche Diagnostics Gmbh | 3 |
| Teco Diagnostics | Teco Diagnostics | 3 |
| Pointe Scientific, Inc. | Horiba Instruments Incorporated | 3 |
| Creatinine plus ver2 | Roche Diagnostics Gmbh | 3 |
| Architect | Abbott Laboratories | 2 |
| CR Cartridge | LifeHealth, LLC | 2 |
| Alinity | Abbott Laboratories | 2 |
| Creatinine LiquiColor® | Stanbio Laboratory, L.P. | 2 |
| Pointe Scientific, Inc. Creatinine Enzymatic | Horiba Instruments Incorporated | 2 |
| Automatic Urine Analyzer | Urit Medical Electronic Co., Ltd. | 2 |
| Creatinine plus ver.2 | Roche Diagnostics Gmbh | 1 |
| Dimension® Flex® reagent cartridge Ezcr | Siemens Healthcare Diagnostics Inc | 1 |
Showing 12 of 40. All products under Enzymatic Method, Creatinine
510(K) Clearances
| Clearance | Decision date |
|---|---|
| K212223 | 2021-11-24 |
| K090330 | 2009-05-22 |
Recalls Naming This Product
4 recalls name this product by its own identifiers, the 510(k) it is cleared under.
| Recalled by | Identified by | Initiated | FDA class | Root cause | Reason | Quantity | Closed |
|---|---|---|---|---|---|---|---|
| Siemens Healthcare Diagnostics Inc | 510(k) number | 2014-09-19 | Class II | Process control | The external power supply for the Clintek Status analyzer, which is provided separately, is damaged. It can result in an electric shock to the User. | approx. 4200 | 2015-07-20 |
| Siemens Healthcare Diagnostics Inc | 510(k) number | 2014-09-19 | Class II | Process control | The external power supply for the Clintek Status analyzer, which is provided separately, is damaged. It can result in an electric shock to the User. | approx. 4200 | 2015-07-20 |
| Siemens Healthcare Diagnostics Inc | 510(k) number | 2014-09-19 | Class II | Process control | The external power supply for the Clintek Status analyzer, which is provided separately, is damaged. It can result in an electric shock to the User. | approx. 4200 | 2015-07-20 |
| Siemens Healthcare Diagnostics Inc | 510(k) number | 2013-02-26 | Class III | Reprocessing Controls | Device with Sample Interference Notes (SIN) enabled not cleared for US marketing. | 1 unit | 2014-05-06 |
Recalls
12 of these are Class II. Class II means a temporary or reversible health consequence. Volume alone is not a quality signal: a manufacturer that ships more recalls more.
| Initiated | FDA class | Root cause | Reason | Quantity | Closed |
|---|---|---|---|---|---|
| 2020-05-04 | Class II | Device Design | The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. | 1006 | 2021-09-20 |
| 2020-05-04 | Class II | Device Design | The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. | 8261 | 2021-09-20 |
| 2020-05-04 | Class II | Device Design | The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. | 23,824 | 2021-09-20 |
| 2020-05-04 | Class II | Device Design | The presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. | 1488 | 2021-09-20 |
| 2019-12-18 | Class II | Under Investigation by firm | There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. | 1,015 units | 2020-06-25 |
| 2019-12-18 | Class II | Under Investigation by firm | There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. | 11,725 units | 2020-06-25 |
| 2019-12-18 | Class II | Under Investigation by firm | There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. | 824 units | 2020-06-25 |
| 2019-12-18 | Class II | Under Investigation by firm | There is a potential for falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology. | 2,198 units | 2020-06-25 |
| 2016-03-17 | Class II | Device Design | Siemens Healthcare Diagnostics has become aware of N-Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. Siemens has confirmed that falsely depressed results may occur on samples drawn | 137422 units total | 2017-09-25 |
| 2016-03-17 | Class II | Device Design | Siemens Healthcare Diagnostics has become aware of N-Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. Siemens has confirmed that falsely depressed results may occur on samples drawn | 137422 units total | 2017-09-25 |
| 2016-03-17 | Class II | Device Design | Siemens Healthcare Diagnostics has become aware of N-Acetylcysteine (NAC) and Metamizole (Dipyrone) interference with Trinder and Trinder-like reaction assays. Siemens has confirmed that falsely depressed results may occur on samples drawn | 137422 units total | 2017-09-25 |
| 2015-07-15 | Class II | Device Design | Siemens has confirmed that the Dimension CREA and Dimension Vista CREA may produce falsely depressed results up to – 12.7% and -22% respectively, for a creatinine concentration of 1.5 mg/dL when hemolysis exceeds 200 mg/dL and 300 mg/dL res | Total number Dimension Vista – 32,165, Dimension – 238,634 | 2017-03-24 |
| 2010-06-10 | Not classified | Device Design | Results may be falsely depressed up to 0.4 mg/dL or falsely elevated up to 0.6 mg/dL across the assay range. | 1,399 | 2013-12-19 |
| 2010-06-10 | Not classified | Device Design | Patient results may be falsely depressed or falsely elevated across the assay range. | 860 | 2013-03-19 |
| 2010-02-12 | Not classified | Nonconforming Material/Component | The ECREA test results may be falsely elevated or depressed. | 324 | 2010-10-13 |
| 2008-09-29 | Not classified | Component design/selection | Reagent may exhibit unflagged inaccurate patient sample results. | 12,773 cartons | 2009-03-27 |
Source: U.S. FDA establishment registration and device listing records, public domain. Restructured for clarity and searchability. Not affiliated with or endorsed by the FDA. Records are records: nothing here is an offer of sale.